Clinical Trials & Patents
FK506 (Tacrolimus) in Pulmonary Arterial Hypertension The trial is completed and does not include any patients.
Rationale: Mutations in bone morphogenetic protein receptor 2 (BMPR2) are present in >80% of familial and ~20% of sporadic pulmonary arterial hypertension (PAH) patients. Furthermore dysfunctional BMP signaling is a general feature of pulmonary hypertension even in non-familial PAH.
We have discovered that FK506 increases BMPR2 signaling and reverses experimental pulmonary hypertension.
- Edda Spiekerkoetter, Md Khadem Ali, Adam Andruska. "United States Use of Tyrosine Kinase Inhibitor for the Treatment of Hereditary Hemorrhagic Telangiectasia and Pulmonary Arterial Hypertension", Leland Stanford Junior University, Nov 22, 2022
- Edda Spiekerkoetter, Svenja Dannewitz, Xuefei Tian, Purvesh Khatri. "United States Patent CA3064275A1 Enzastaurin and Fragile Histidine Trial (FHIT) Increasing Agents for the Treatment of Pulmonary Hypertension", Leland Stanford Junior University, May 18, 2018
- Edda Spiekerkoetter, Marlene Rabinovitch, David Solow-Cordero, Phil Beachy. "United States Patent 61481317 Low-Dose FK506 for the treatment of Pulmonary Arterial Hypertension", Leland Stanford Junior University, May 2, 2012